The Systemic Renin-Angiotensin System in COVID-19

Roman Reindl-Schwaighofer

Medical University of Vienna

Sebastian Hödlmoser

Medical University of Vienna

Oliver Domenig

Attoquant Diagnostics

Katharina Krenn

Medical University of Vienna

Farsad Eskandary

Medical University of Vienna

Simon Krenn

Medical University of Vienna

Christian Schörgenhofer

Medical University of Vienna

Benedikt Rumpf

Klinik Favoriten

Mario Karolyi

Klinik Favoriten

Marianna T. Traugott

Klinik Favoriten

Agnes Abrahamowicz

Klinik Favoriten

Viktoria Tinhof

Medical University of Vienna

Hannah Mayfurth

Medical University of Vienna

Vincent Rathkolb

Medical University of Vienna

Sebastian Mußnig

Medical University of Vienna

Lukas Schmölz

Medical University of Vienna

Roman Ullrich

Medical University of Vienna

Andreas Heinzl

Medical University of Vienna

Franz König

Medical University of Vienna

Christina Binder

Medical University of Vienna

Diana Bonderman

Klinik Favoriten

Robert Strassl

Medical University of Vienna

Elisabeth Puchhammer-Stöckl

Medical University of Vienna

Gregor Gorkiewicz

Medical University of Graz

Judith H. Aberle

Medical University of Vienna

Bernd Jilma

Medical University of Vienna

Christoph Wenisch

Klinik Favoriten

Marko Poglitsch

Attoquant Diagnostics

Rainer Oberbauer

Medical University of Vienna

Alexander Zoufaly

Sigmund Freud University

Manfred Hecking (✉ manfred.hecking@meduniwien.ac.at)

Medical University of Vienna

Article

Keywords:

Posted Date: July 5th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1381017/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Introduction:

SARS-CoV-2 gains cell entry via angiotensin-converting enzyme (ACE) 2, a membrane-bound enzyme of the “alternative” (alt) renin-angiotensin system (RAS). ACE2 counteracts angiotensin II by converting it to potentially protective angiotensin 1–7.

Methods

Using mass spectrometry, we assessed key metabolites of the classical RAS (angiotensins I–II) and alt-RAS (angiotensins 1–7 and 1–5) pathways as well as ACE and ACE2 concentrations in 159 patients hospitalized with COVID-19, stratified by disease severity (severe, $n = 76$; non-severe: $n = 83$). Plasma renin activity (PRA-S) was calculated as the sum of RAS metabolites. We estimated ACE activity using the angiotensin II:I ratio (ACE-S) and estimated systemic alt-RAS activation using the ratio of alt-RAS axis metabolites to PRA-S (ALT-S). We applied mixed linear models to assess how PRA-S and ACE/ACE2 concentrations affected ALT-S, ACE-S, and angiotensins II and 1–7.

Results

Median angiotensin I and II levels were higher with severe versus non-severe COVID-19 (both $p < 0.05$), demonstrating activation of classical RAS. The difference disappeared with analysis limited to patients not taking a RAS inhibitor. ALT-S in severe COVID-19 increased with time (days 1–6: 0.12; days 11–16: 0.22) and correlated with ACE2 concentration ($r = 0.831$). ACE-S was lower in severe versus non-severe COVID-19 ($p < 0.001$), but ACE concentrations were similar between groups and weakly correlated with ACE-S ($r = 0.232$). ACE2 and ACE-S trajectories in severe COVID-19, however, did not differ between survivors and non-survivors. Overall RAS alteration in severe COVID-19 resembled severity of disease-matched patients with influenza. In mixed linear models, renin activity most strongly predicted angiotensin II and 1–7 levels. ACE2 also predicted angiotensin 1–7 levels and ALT-S. No single factor or the combined model, however, could fully explain ACE-S. ACE2 and ACE-S trajectories in severe COVID-19 did not differ between survivors and non-survivors.

Conclusions

Angiotensin II was elevated in severe COVID-19 but markedly influenced by RAS inhibitors and driven by overall RAS activation. ACE-S was significantly lower with severe COVID-19 and did not correlate with ACE concentrations. A shift to the alt-RAS axis because of increased ACE2 could partially explain the relative reduction in angiotensin II levels.

Background

The renin-angiotensin system (RAS) is a complex network that regulates blood pressure and blood volume through the hormone angiotensin II via its type 1 (AT₁) receptor ('classical' RAS) (1). Angiotensin 1–7 acts via an 'alternative' RAS pathway. It partially antagonizes AT₁ receptor-mediated effects such as vasoconstriction, fibrosis, and thrombogenesis by signaling through the G-protein-coupled Mas receptor, which promotes vasodilation and anti-fibrotic actions (2). Although angiotensin-converting enzyme (ACE), a carboxypeptidase, drives angiotensin II formation from angiotensin I, ACE2 opposes its action through conversion of angiotensin II to angiotensin 1–7 (3).

Severe Acute Respiratory Syndrome (SARS)–Coronavirus (CoV)-2 uses ACE2 as its primary entry receptor into human cells (4). ACE2 is a membrane-anchored protein expressed on the surface of type II alveolar cells and epithelial cells of the lung. It also is present in many other tissues, including the intestine, kidney, and heart, and can be shed following cleavage by ADAM17 (5). COVID-19, the disease caused by SARS-CoV-2, has a highly variable clinical presentation and severity, with age, male sex, and comorbidities such as diabetes and hypertension associated with increased severity risk (6).

The assumption that the RAS becomes dysregulated in COVID-19 is based on experimental data showing that ACE2 is downregulated in the lungs of wild-type mice infected with SARS-CoV (7). This downregulation was inferred to contribute to lung damage by impairing angiotensin II degradation (7, 8), and systemic angiotensin II infusion in a large animal model led to lung injury closely resembling COVID-19 (9). Furthermore, in one hospital study, angiotensin II levels were elevated in 12 patients with COVID-19 compared with eight healthy controls, and were associated with a higher SARS-CoV-2 viral load and lower PaO₂/FiO₂ ratio as a read-out for lung injury (10).

We recently reported that endogenous enzymatically active ACE2 is increased in severe COVID-19 to concentrations that may significantly affect systemic RAS regulation (11). In the present study, we compared changes in classical and alternative RAS regulation between patients with severe versus non-severe COVID-19.

Methods

Study cohort and sampling

The study cohort comprises patients with PCR-confirmed SARS-CoV-2 infection who were hospitalized for COVID-19 at Klinik Favoriten in Vienna, Austria, from March 15 to September 30, 2020, and enrolled in the Austrian COronaVirus Adaptive Clinical Trial (ACOVACT, registered with clinicaltrials.gov [NCT04351724]). This study was approved by the Ethics Committee of the Medical University of Vienna [#1315/2020]). ACOVACT is a multicenter, randomized, active-controlled, open-label platform trial to evaluate the efficacy and safety of therapeutics for COVID-19. Serum or plasma was sampled up to three times weekly in hospitalized patients. Patients provided written informed consent to participate. To place the RAS

regulation status of Covid-19 patients into context with other states of health and disease, we measured RAS profiles in 16 healthy individuals and re-analyze RAS data from 27 critically ill patients with influenza pneumonia included in a previous study, serving as controls (11).

Data extraction and assessment of clinical status

Data extraction was done by chart review. RAS medication status was defined as treatment with a pharmacological RAS inhibitor at the time of hospitalization, confirmed by direct measurement of drug concentration in the circulation. COVID-19 severity was defined by the maximum requirement for respiratory support during hospitalization and categorized as severe (invasive and non-invasive ventilation, including high-flow nasal cannula oxygen therapy; WHO scale 6–10) and non-severe (all other hospitalized patients; WHO scale 4,5)(12).

Angiotensin quantification (RAS-Fingerprint)

The equilibrium levels of six angiotensin peptide metabolites (angiotensins I–IV, angiotensin 1–7, angiotensin 1–5) in human heparinized plasma samples were quantified by liquid chromatography-mass spectrometry/mass-spectroscopy (LC-MS/MS) using previously described methods (13, 14). The biochemical background of the equilibrium approach has recently been validated (15, 16). To calculate overall RAS activity, we used the sum of RAS metabolites (angiotensins I–IV, 1–7, and 1–5) to yield a plasma renin activity (PRA-S) value. To estimate ACE activity, we took the ratio of angiotensins I and II, yielding an activity marker for ACE, the ACE-S. For an estimate of systemic alternative RAS pathway activity (ALT-S), we calculated the ratio of the sum of alternative RAS metabolites (angiotensins 1–7 and 1–5) and the PRA-S value as previously described (17, 18).

Measurement of ACE and ACE2

ACE and ACE2 concentrations were determined after samples were spiked with their respective substrates (angiotensin I for ACE and angiotensin II for ACE2) and incubated at 37°C with or without specific inhibitors (ACE: 10 µM lisinopril; ACE2: 10 µM MLN-4760). We used LC-MS/MS to quantify the obtained products (angiotensin II from ACE activity; angiotensin 1–7 from ACE2 activity). To calculate the enzyme-specific angiotensin formation rate and determine active ACE and ACE2 concentrations, we used a calibration curve of recombinant human ACE (R&D Systems, Minneapolis, MN, USA) over ACE2 in human serum or plasma.

Measurement of RAS inhibitor medications

Following methanol precipitation, samples were diluted in injection buffer (10% acetonitrile/0.1% formic acid) and subjected to mass spectrometry analysis using a reversed analytical column (Acquity UPLC C18, Waters) operating in line with a XEVO TQ-S triple quadrupole mass spectrometer (Waters Xevo TQ/S, Milford, MA, USA) in multiple reaction monitoring mode. Drug concentrations (candesartan, valsartan, losartan, olmesartan, telmisartan, enalaprilat, lisinopril, perindoprilat, ramiprilat) were calculated from integrated chromatograms, considering the corresponding response factors determined in appropriate calibration curves for the serum matrix when integrated signals exceeded a signal-to-noise ratio of 10.

Ex vivo assessment of ALT-S at different ACE2 levels

The alternative RAS (ALT-S) was investigated in in pooled serum samples following addition of different concentrations of recombinant human ACE2 (rhACE2).

Statistical analysis

Patient characteristics are described by medians and first and third quartiles for continuous variables and frequencies and percentages for categorical variables. Groups were compared using Student's t-test for continuous variables with normal distribution and chi-squared and Fisher's exact tests for categorical variables. The starting point for all analyses over time was the day of hospitalization for SARS-CoV-2. Because of multiple measurements per patient, to compare changes over time, we calculated mean angiotensin levels during the hospital stay and over 5-day time intervals. Values for biomarkers were largely not normally distributed, so we used Mann-Whitney U tests to compare angiotensin levels between severity groups (severe versus non-severe). To visualize selected angiotensin levels over time, we used non-parametric smoothing (i.e., the *loess* function in R) in conjunction with local 95% confidence intervals. In addition, we employed boxplots to visualize ACE2 concentrations and angiotensin levels in the two disease severity groups and across 5-day intervals. We generated scatterplots of selected angiotensin pairs (on a log axis where necessary), color-coded by disease severity or ACE2 value (on a logarithmic color scale), and reported Spearman correlation coefficients.

To evaluate associations of levels of the RAS-Fingerprint components (ACE-S, ALT-S, angiotensin 1–7, angiotensin II) with other variables, we fitted linear mixed effects models with random intercept per patient, with varying independent variables (separate models using PRA-S, ACE, and ACE2, and a combined model with all three as covariates). Dependent variables as well as covariates were log transformed. Models were compared using pseudo R^2 for generalized mixed effects models, specifically by the marginal R^2 , denoted by R^2_m .⁽¹⁹⁾ This type of statistic represents the variance explained by the fixed effects, so we interpret it as a goodness-of-fit indicator at the population level. We considered two-sided $p < 0.05$ as indicating statistical significance. Because we did not test a specific hypothesis and used statistical tests purely for descriptive purposes, we did not adjust p values for multiple testing. All calculations and statistical analyses were performed using R 4.0.1.

Funding

The study was supported by the Austrian Science Fund (FWF grant KLI 861-B) and by the Medical-scientific fund of the Mayor of the federal capital Vienna (grant MA 40-GMWF-COVID027).

Results

Characteristics of the study patients and clinical outcomes

A total of 159 patients, all hospitalized with COVID-19, were included in the study. Baseline characteristics and clinical parameters of the patients, stratified by COVID-19 severity (severe versus non-severe), are provided in **Table 1**. The median age across the whole group was 66 years, and 32.9% were women, with no significant differences between disease severity groups. Of the entire study cohort, 19.6% and 24.7% of patients received an ACE inhibitor (ACEi) or an angiotensin receptor blocker (ARB) at baseline and during the study, respectively.

Median in-hospital length of stay was 28 days for those with severe disease and 14 days for those with non-severe COVID-19. All patients were followed until discharge or death. A total of 15 patients died, corresponding to a mortality rate of 23.7% with severe disease versus 2.4% with non-severe COVID-19.

Overall RAS activity

A total of 680 samples were available for RAS analysis (complete RAS profiles were available for 511 samples; RAS enzyme quantification alone was performed for the remaining 169 samples). Median systemic angiotensin levels stratified by disease severity and across 5-day intervals following hospitalization are reported in **Table 2A** and **2B**. In severe versus non-severe COVID-19, we observed an overall RAS activation with higher angiotensin I and angiotensin II levels (86 versus 30 pmol/L angiotensin I, $p<0.01$; 114 versus 58 pmol/L angiotensin II, $p<0.05$; **Figure 1A** and **1B**). In line with this pattern, PRA-S was also elevated in severe compared with non-severe COVID-19 (**Figure 2A**). Overall, the highest angiotensin I and II levels overall were observed in invasively ventilated, critically ill patients ($n=44$; 271 pmol/L angiotensin I and 207 pmol/L angiotensin II, **Table S3**).

We also assessed RAS profiles in the subgroup of 92 patients not receiving RAS inhibitors (**Table S1**) and found that the difference in classical RAS activation by severity had vanished (severe versus non-severe COVID-19, respectively: 40 versus 31 pmol/L angiotensin I, $p=0.251$; and 76 versus 99 pmol/L angiotensin II, $p=0.833$; **Table 2A**, **Table S2**). Conversely, activation of the classical RAS at time of hospitalization was highest in severe COVID-19 patients on RASi treatment (**Table S4**). In line to the drugs mechanism of action, patients on ACEi treatment at time of hospitalization had higher angiotensin I levels, while patients on ARB showed higher angiotensin II levels.

RAS profiles in healthy individuals differed from COVID-19 showing lower Angiotensin I but higher Angiotensin II levels (**Table S5**). Angiotensin levels in mechanically ventilated influenza patients were comparable to severity of disease matched COVID-19 patients requiring mechanical ventilation (**Table S6**; median Sequential Organ Failure Assessment [SOFA] score of 9 [8-11] and 9 [8-11] for mechanically ventilated COVID-19 and influenza patients).

Alternative RAS

In contrast to the pattern for overall RAS activity, we observed a marked increase in angiotensin 1-7 and angiotensin 1-5 levels in severe COVID-19, in line with an overall shift to the alternative RAS, independent of RAS inhibitor use (**Table 2A** and **2B**, **Figure 1A** and **1B**, **Figure 3A** and **3B**). The increase in the alternative RAS component angiotensin 1-7 (and its downstream metabolite angiotensin 1-5) was highly correlated with systemic ACE2 concentrations ($r=0.831$; **Figure 2B** and **Figure 3C**). The ALT-S (as ratio of alternative RAS metabolites on the total RAS activity) in severe COVID-19 increased from 10% during days 1–6 to 21% during days 11–16 of hospitalization (showing a shift to alternative RAS metabolites). Overall, angiotensin I and angiotensin 1-7 levels were highly correlated ($r=0.827$), but ACE2 modified this relationship, and angiotensin 1-7 levels were relatively higher with higher ACE2 concentrations (**Figure 3D**). Alternative RAS activation findings were similar in the subgroup of patients not taking RAS inhibitors (**Table 2A**).

Of interest, ALT-S plateaued at ACE2 levels >100 ng/mL (**Figure 3C**). We observed a similar plateau in an in vitro experiment using different concentrations of recombinant ACE2 in pooled plasma samples. These findings suggest that a limited availability of angiotensin II prevented production of higher levels of angiotensin 1-7 and angiotensin 1-5 (black squares, **Figure 3C**).

ALT-S in healthy individuals was 0.04, while ALT-S was elevated in critically ill influenza patients but overall lower compared to ALT-S in mechanically ventilated COVID-19 patients (0.14 and 0.24 for critically-ill influenza and COVID-19, respectively; Tables S5 and S6). ALT-S was highly correlated with ACE2 in patients with influenza ($r=0.821$).

ACE-S

The systemic activity of ACE, estimated by the angiotensin-II-to-angiotensin-I ratio (ACE-S), was markedly lower with severe versus non-severe COVID-19 (1.6 vs 2.6), suggesting decreased functional ACE activity (**Figure 4A** and **4B**). ACE concentration, however, was similar between the two groups (**Table 2A** and **Table 2B**, **Figure 2C**), and the correlation between ACE-S and ACE concentration was weak ($r=0.232$). When we excluded patients on RAS inhibitors, the correlation increased but remained rather weak ($r=0.331$; **Figure 4C**). The possibility of unaccounted use of RAS inhibitors as a potential confounder in individuals with low intrinsic ACE activity (<2) was ruled out by direct measurement in patient sera for most RAS inhibitors (ACE inhibitors: enalaprilat, lisinopril, perindoprilat, ramiprilat; angiotensin receptor blockers: candesartan, valsartan, losartan, olmesartan, telmisartan).

We explored potential factors contributing to the reduced intrinsic ACE activity in severe COVID-19 with and without use of RAS inhibitors. **Figure 4D** shows the correlation between angiotensin I and angiotensin II, and thus ACE-S values, with lower values lying below the regression line and higher values above it. Overall, angiotensin I and II correlated strongly across all stages of overall RAS activity ($r=0.756$ for all patients and $r=0.897$ for patients not taking RAS inhibitors). For samples with values below the regression line (i.e., with lower ACE-S), however, we observed higher ACE2 levels. In line with this pattern,

ACE2 levels showed a moderate negative correlation with ACE-S ($r=-0.358$ for all patients and -0.535 for patients not taking RAS inhibitors; **Figure 4E**). Furthermore, PRA-S showed a moderate negative correlation with ACE-S ($r=-0.347$ for all patients and $r=-0.357$ for patients not taking RAS inhibitors; **Figure 4F**).

ACE-S in healthy individuals was 4.7 and thus higher compared to COVID-19 patients (Table S5). In patients with severe influenza, however, ACE-S was also decreased and comparable to patients with severe COVID-19 (1.49 and 1.51, respectively; Tables S6).

Explanatory models

We subsequently applied mixed models to analyze the influence of RAS activity (assessed by PRA-S and concentrations of ACE and ACE2) on angiotensin II and angiotensin 1-7 levels as well as on ACE-S and ALT-S in patients without RAS inhibitory medication (**Figure 5**, data for all patients is provided in **Figure S1**). We found that 94% of the variance in angiotensin II concentration was explained by the fixed effects of angiotensin I ($=0.826$), and the model could be improved only slightly by the addition of ACE and ACE2 ($=0.882$). The variance in angiotensin 1-7 concentration was partly explained by angiotensin I ($=0.519$), followed by ACE2 ($=0.305$), and their combination together with ACE explained more than 70% of its variance ($=0.740$). The variance of ALT-S was explained by ACE2 ($=0.551$), and the model could be improved by adding angiotensin I and ACE ($=0.716$). The ACE-S model, however, showed the poorest goodness of fit when only one of each of the covariates was used (angiotensin I: $=0.161$; ACE: $=0.081$; ACE2: $=0.188$). Even the combined model still explained only ~40% of the variance of ACE-S ($=0.478$).

Outcome

Lastly, we compared trajectories of ACE2 and ACE-S in patients with severe COVID-19 with respect to outcome (**Figure 6**, only severe patients included [$n=76$]). However, despite the increase in ACE2 over time in severe COVID-19 patients (**Figure 2C**), trajectories for ACE2 did not differ between survivors and non-survivors (**Figure 6A**). Similarly, despite lower ACE-S in severe COVID-19 patients (**Figure 4A**), trajectories for ACE-S did not differ between survivors and non-survivors (**Figure 6B**).

Discussion

In the present study, we analyzed systemic RAS in patients who were hospitalized with COVID-19. We predicted that the interaction between SARS-CoV-2 and ACE2 would result in systemic RAS dysregulation. (4, 6) Our main findings were (i) that the observed increase in angiotensin II levels in severe COVID-19 was driven by an overall RAS activation and highest in mechanically ventilated patients and in those on RAS inhibitors; (ii) that the angiotensin II:I ratio as a marker for ACE activity (ACE-S) was reduced in severe COVID-19 and did not correlate with ACE concentration; (iii) that RAS was shifted to the alternative RAS

axis with an increase in angiotensin 1–7 levels rather than angiotensin II; (iv) the shift to the alternative RAS axis was highly correlated with an increase in systemic ACE2 concentration; and (v) RAS profiles in most severe COVID-19 patients requiring mechanical ventilation resembled RAS profiles in severity of disease matched influenza patients.

The low ACE-S observed in severe COVID-19 (and influenza) could have resulted from decreased angiotensin II formation from angiotensin I or from increased enzymatic degradation of angiotensin II. ACE2 primarily mediates the latter, degrading angiotensin II to angiotensin 1–7 and counterbalancing the effects of angiotensin II. ACE2 has been described as a biomarker in various pathologic conditions, including hypertension and heart failure (20), and occupies a central position in the pathophysiology of COVID-19.

Despite this association, some features of a proposed RAS dysregulation in COVID-19 suggested so far are hypothetical with respect to the human system: Kuba et al. used mouse models for their finding that SARS-CoV infection and the spike protein of SARS-CoV alone reduced ACE2 expression in the lungs (7). Based on that study, many researchers suggested that in COVID-19, a lack of ACE2 activity following SARS-CoV-2 infection causes an increase in angiotensin II that might mediate lung injury. Of note, systemic RAS activity was not investigated in these studies, and the reported increase in local lung angiotensin II might in part have arisen from increased plasma renin activity, culminating in an increased rate of angiotensin II formation in the lungs. Previous studies have shown that in critically ill patients (including those with influenza), renin activity and angiotensin II levels correlate with tissue injury, disease severity, and outcome (21, 22). Early reports including RAS data from 12 patients hospitalized for COVID-19 in Shenzhen (half of whom developed acute respiratory distress syndrome, or ARDS), showed that angiotensin II levels in severe COVID-19 were higher than in healthy controls and associated with viral load and lung injury (10). We previously reported elevated angiotensin II levels in invasively ventilated COVID-19 patients in our cohort (11).

In the present dataset, however, the angiotensin II elevation disappeared after we excluded patients on RAS inhibitors and was most likely a consequence of compensatory upregulation of renin in response to RAS blocker treatment rather than from the impaired degradation of angiotensin II by functional ACE2 deficiency. ARB and ACEi treatments are well known to cause increased renin activity (23). These data underline the importance of accounting for RAS inhibitory medication in studies analyzing angiotensin profiles. The observed elevation in angiotensin II levels in critically ill patients may further be primarily attributable to hemodynamic instability and overall disease severity (including extra-pulmonary organ failure) rather than being a specific effect of SARS-CoV-2-mediated lung injury. In line with this reasoning, another study found no elevation in angiotensin levels in COVID-19 patients who were compared to “severity-of-disease” matched controls with respiratory failure (24). In yet another study, the authors found that a decrease in serum angiotensin II levels in COVID-19 patients was correlated with subsequent lung damage (25).

Remarkably, in the present study, systemic ACE2 in patients with severe COVID-19 increased to levels that profoundly affected systemic angiotensin metabolites, as shown by an increase in the ALT-S and in angiotensin 1–7 levels. The strong correlation between ACE2 and ALT-S provides evidence for unimpaired activity of the increased levels of soluble ACE2 (while it has been proposed that enzymatically inactive, truncated ACE2 variants are upregulated by inflammation) and for enzymatic cleavage of angiotensin II to angiotensin 1–7 primarily by ACE2 (and not by another unspecified peptidase) (26). We have recently shown that ACE2 increases in bronchoalveolar lavage fluid following lipopolysaccharide instillation in a human endotoxemia model (27). To our best understanding, our data both add to our previous findings (11) and align perfectly with an autopsy study from Belgium showing increased pulmonary ACE2 expression and decreased ACE expression in ARDS with or without COVID-19, when compared with unaffected controls (28). Of interest, as in our previous (11) and present work, researchers in Canada reported an upward trajectory of soluble ACE2 at 7-day sampling (from baseline) that was independently associated with increased mortality risk among their 242 patients with COVID-19 (29). A relationship among ACE2, disease severity, and mortality emerged in yet another analysis, this one from Hungary, of 176 patients with COVID-19 (30), and five additional studies have demonstrated elevated to highly elevated ACE2 levels in COVID-19 (31–35). Three other studies found no ACE2 elevation in COVID-19 (36–38), possibly because the included patients were less severely affected and/or ACE2 was measured only at the beginning of the disease course.

Interestingly, ALT-S was also elevated in mechanically ventilated patients with influenza: We have previously also reported an increase in ACE2 in patients with influenza, although levels were lower compared to mechanically ventilated patients with COVID-19. Importantly no longitudinal data were available for patients with influenza and changes over time could not be assessed.

The observed increase in ACE2 in COVID-19 patients, however, could only partly explain the observed reduction in ACE-S in severe COVID-19 that we identified in our descriptive mixed linear models. This result suggests that the relative decrease in angiotensin II levels is further influenced by an unaccounted enzymatic degradation of angiotensin II (in addition to the action of ACE2) to unmeasured downstream metabolites, or by the presence of an intrinsic functional ACEi. ACE-S was also reduced in our comparator group of patients with severe influenza. We note that reduced ACE activity has been described in patients with ARDS and sepsis and was associated with adverse outcome (39, 40). In ARDS patients the observed reduced ACE-S was also not associated with altered ACE protein levels (39).

A major strength of the current work is the longitudinal assessment of changes in RAS metabolite concentrations in individual patients over the course of the disease. The shift to the alternative RAS axis was time dependent and increased with time, and the intrinsic ACE activity in severe COVID-19 was already low at hospitalization. A recent study showed that in patients who recovered from COVID-19, ACE2 levels remained elevated for up to 3 months following infection, suggesting that RAS dysregulation in COVID-19 may persist after the acute illness resolves (31). However, our analysis is limited to key enzymatic pathways of the classical and alternative RAS. Although we identified ACE2 as an important mediator of reduced intrinsic ACE activity in severe COVID-19, a significant portion of this reduction

remained unaccounted for, and alternative pathways of angiotensin II degradation or endogenous ACE inhibition should be sought in subsequent studies.

Limitations of our study are primarily owed to the observational study character that does not allow to infer causal relations of RAS dysregulation and disease severity. Recent experimental data suggest that the RAS represents a druggable target in severe lung injury (41). Similar RAS profiles in patients with severe influenza suggest that changes may represent a more general response to severe lung injury or critical illness rather than COVID-19-specific alterations. The control group however lacks longitudinal data and warrants further research in RAS (dys)regulation in critically ill patients.

In conclusion, the current findings provide evidence for profound alteration in systemic RAS regulation in COVID-19. Specifically, in severe COVID-19, we observed a reduced angiotensin II:I ratio, used as a marker for functional ACE activity, a reduction that was partially explained by an overall shift to the alternative RAS axis because of increased ACE2 levels. These data add to our mechanistic understanding of COVID-19 and prompted us to hypothesize the existence of an unidentified enzymatic degradation of angiotensin II (in addition to ACE2) or the presence of an unidentified intrinsic functional inhibitor of ACE.

Declarations

Ethical Approval and Consent to participate

The Austrian COronaVirus Adaptive Clinical Trial (ACOVACT) was approved by the Ethics Committee of the Medical University of Vienna (#1315/2020) and registered with clinicaltrials.gov (NCT04351724). All participating individuals were adults and provided their written, informed consent to participate. The study was conducted in accordance with the principles of the Declaration of Helsinki.

Consent for publication

All authors reviewed the manuscript and approved the manuscript / gave consent for publication.

Authors' contributions

R.R.-S., M.H., F.E., C.S. and R.O. conceptualized the study.

S.H., A.H., F.K. and R.R.-S. analyzed the data.

O.D. and M.P. performed RAS measurements and helped with data interpretation.

K.K., R.U., C.B. and D.B. contributed additional data.

C.S. and B.J. communicated with the ethics committee and submitted the study for approval.

B.R., M.K. and M.T.T. included patients into the study.

A.A., V.T., H.M., V.R. and L.S. performed the data collection.

R.S., E.P.-S. and J.H.A. did SARS-CoV-2 analyses.

G.G. contributed data from pathology.

C.W. and A.Z. were in charge of patient inclusion.

R.R.-S. and S.H. made the figures.

R.R.-S., S.H. and M.H. wrote the manuscript.

F.E., S.K., C.S., O.D., M.P., K.K., R.U., C.S., B.J., B.R., C.W. and R.O. corrected the manuscript.

All authors reviewed the manuscript.

Data availability statement

Data are available from the authors upon reasonable request (roman.reindl-schwaighofer@meduniwien.ac.at)

Declaration of interests

Marko Poglitsch and Oliver Domenig are employed by Attoquant Diagnostics, Vienna/Austria, a company that received payments for RAS-Fingerprint and ACE2 measurements. None of the other co-authors declared a competing interest related to the present manuscript.

Acknowledgements

We thank Andreas Rosenstingl and Florian Martys for excellent data management.

References

1. Vaduganathan M, Vardeny O, Michel T, et al: Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med* 2020; 382(17):1653–1659
2. Bader M, Alenina N, Young D, et al: The Meaning of Mas. *Hypertension* 2018; 72(5):1072–1075
3. Kuba K, Imai Y, Penninger JM: Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. *Circ J* 2013; 77(2):301–308
4. Hoffmann M, Kleine-Weber H, Schroeder S, et al: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020
5. Patel VB, Clarke N, Wang Z, et al: Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. *J Mol Cell Cardiol* 2014; 66:167–176
6. Zhou P, Yang XL, Wang XG, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; 579(7798):270–273

7. Kuba K, Imai Y, Rao S, et al: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 2005; 11(8):875–879
8. Li MY, Li L, Zhang Y, et al: Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infect Dis Poverty* 2020; 9(1):45
9. Rysz S, Al-Saadi J, Sjöström A, et al: COVID-19 pathophysiology may be driven by a loss of inhibition of the Renin-Angiotensin-Aldosterone System <https://www.researchsquare.com/article/rs-32494/v2>.
10. Liu Y, Yang Y, Zhang C, et al: Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci* 2020; 63(3):364–374
11. Reindl-Schwaighofer R, Hodlmoser S, Eskandary F, et al: Angiotensin-Converting Enzyme 2 (ACE2) Elevation in Severe COVID-19. *Am J Respir Crit Care Med* 2021
12. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis* 2020; 20(8):e192-e197
13. Guo Z, Poglitsch M, McWhinney BC, et al: Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism. *Clin Chem* 2020; 66(3):483–492
14. Urwyler SA, Ebrahimi F, Burkard T, et al: IL (Interleukin)-1 Receptor Antagonist Increases Ang (Angiotensin [1–7]) and Decreases Blood Pressure in Obese Individuals. *Hypertension* 2020; 75(6):1455–1463
15. Basu R, Poglitsch M, Yogasundaram H, et al: Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. *J Am Coll Cardiol* 2017; 69(7):805–819
16. Antlanger M, Domenig O, Kovarik JJ, et al: Molecular remodeling of the renin-angiotensin system after kidney transplantation. *J Renin Angiotensin Aldosterone Syst* 2017; 18(2):1470320317705232
17. Guo Z, Poglitsch M, Cowley D, et al: Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism. *Hypertension* 2020; 76(2):488–496
18. Zoufaly A, ... Penninger JM: Human recombinant soluble ACE2 in severe COVID-19; DOI:[https://doi.org/10.1016/S2213-2600\(20\)30418-5](https://doi.org/10.1016/S2213-2600(20)30418-5). *Lancet Respiratory Medicine* 2020
19. Nakagawa S, Johnson PCD, Schielzeth H: The coefficient of determination R(2) and intra-class correlation coefficient from generalized linear mixed-effects models revisited and expanded. *J R Soc Interface* 2017; 14(134)
20. Narula S, Yusuf S, Chong M, et al: Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. *Lancet* 2020; 396(10256):968–976
21. Gleeson PJ, Crippa IA, Mongkolpun W, et al: Renin as a Marker of Tissue-Perfusion and Prognosis in Critically Ill Patients. *Crit Care Med* 2019; 47(2):152–158
22. Huang F, Guo J, Zou Z, et al: Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. *Nat Commun* 2014; 5:3595

23. Chen L, Kim SM, Eisner C, et al: Stimulation of renin secretion by angiotensin II blockade is Gsalpha-dependent. *J Am Soc Nephrol* 2010; 21(6):986–992
24. Files DC, Gibbs KW, Schaich CL, et al: A pilot study to assess the circulating renin-angiotensin system in COVID-19 acute respiratory failure. *Am J Physiol Lung Cell Mol Physiol* 2021; 321(1):L213-L218
25. Ozkan S, Cakmak F, Konukoglu D, et al: Efficacy of Serum Angiotensin II Levels in Prognosis of Patients With Coronavirus Disease 2019. *Crit Care Med* 2021; 49(6):e613-e623
26. Onabajo OO, Banday AR, Yan W, et al: Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2. *bioRxiv* 2020
27. Reindl-Schwaighofer R, Eskandary F, Bartko J, et al: Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid. *Front Med (Lausanne)* 2022; 9:856891
28. Gerard L, Lecocq M, Bouzin C, et al: Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19-related Acute Respiratory Distress Syndrome. *Am J Respir Crit Care Med* 2021; 204(9):1024–1034
29. Wang K, Gheblawi M, Nikhanj A, et al: Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries. *Hypertension* 2021:HYPERTENSIONAHA12118295
30. Fagyas M, Fejes Z, Suto R, et al: Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patients. *Int J Infect Dis* 2021; 115:8–16
31. Patel SK, Juno JA, Lee WS, et al: Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. *Eur Respir J* 2021; 57(5)
32. van Lier D, Kox M, Santos K, et al: Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients. *ERJ Open Res* 2021; 7(1)
33. Kragstrup TW, Singh HS, Grundberg I, et al: Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients. *PLoS One* 2021; 16(6):e0252799
34. Kaur G, Yogeswaran S, Muthumalage T, et al: Persistently Increased Systemic ACE2 Activity Is Associated With an Increased Inflammatory Response in Smokers With COVID-19. *Front Physiol* 2021; 12:653045
35. Nagy B, Jr., Fejes Z, Szentkereszty Z, et al: A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient. *Int J Infect Dis* 2021; 103:412–414
36. Kintscher U, Slagman A, Domenig O, et al: Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System. *Hypertension* 2020; 76(5):e34-e36
37. Rieder M, Wirth L, Pollmeier L, et al: Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19. *Am J Hypertens* 2021; 34(3):278–281
38. Rojas M, Acosta-Ampudia Y, Monsalve DM, et al: How Important Is the Assessment of Soluble ACE-2 in COVID-19? *Am J Hypertens* 2021; 34(3):296–297

39. Krenn K, Hobart P, Poglitsch M, et al: Equilibrium Angiotensin Metabolite Profiling in Patients with Acute Respiratory Distress Syndrome Indicates Angiotensin-Converting Enzyme Inhibition. Am J Respir Crit Care Med 2020; 202(10):1468–1471
40. Bellomo R, Wunderink RG, Szerlip H, et al: Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care 2020; 24(1):43
41. Mao X, Krenn K, Tripp T, et al: Tidal Volume-Dependent Activation of the Renin-Angiotensin System in Experimental Ventilator-Induced Lung Injury. Crit Care Med 2022

Tables

Table 1. Demographic and clinical characteristics of the study cohort.

	Non-severe (n=83)	Severe (n=76)	Total (N=159)	P
Age	67.0 [52.5, 79.3]	64.5 [52.3, 73.0]	65.5 [52.3, 76.8]	0.613
Female	31 (39.2%)	19 (26.0%)	50 (32.9%)	0.057
BMI	27.7 [24.8, 30.6]	25.8 [24.5, 30.7]	26.5 [24.5, 30.8]	0.947
ACEi	17 (20.5%)	14 (18.7%)	31 (19.6%)	0.774
ARB	20 (24.1%)	19 (25.3%)	39 (24.7%)	0.857
Diabetes	22 (26.5%)	24 (32.0%)	46 (29.1%)	0.448
Hypertension	49 (59.0%)	49 (65.3%)	98 (62.0%)	0.415
COPD	5 (6.0%)	12 (16.0%)	17 (10.8%)	0.043
Hospital length of stay (days)	14.0 [10.0, 25.0]	28.0 [16.8, 33.3]	21.0 [12.0, 30.0]	<0.001
Death	2 (2.4%)	18 (23.7%)	20 (12.6%)	<0.001

Continuous variables are presented as medians [with first, third quartiles), and binary variables are presented as absolute numbers (with %).

Table 2. RAS analysis in patients with COVID-19.

Table 2A. Across all time points

	All patients			No ACEi/ARB		
	Non-severe	Severe	P	Non-severe	Severe	P
Angiotensin I	29.91 [9.03, 72.54]	85.50 [26.00, 321.62]	<0.01*	30.66 [7.29, 64.39]	40.19 [10.20, 232.31]	0.251
Angiotensin II	58.17 [16.83, 131.78]	114.30 [52.16, 236.14]	<0.05*	98.57 [25.66, 169.77]	76.28 [31.55, 215.08]	0.833
Angiotensin 1-5	3.37 [1.76, 8.70]	13.26 [5.01, 48.55]	<0.001*	4.06 [1.97, 9.49]	10.22 [2.71, 45.16]	0.051
Angiotensin 1-7	1.97 [1.50, 6.84]	9.92 [2.80, 38.03]	<0.001*	1.93 [1.50, 5.29]	7.11 [1.50, 31.28]	<0.05*
PRA-S	130.75 [39.44, 254.74]	293.80 [129.67, 681.86]	<0.05*	148.38 [39.47, 250.81]	139.31 [45.50, 473.49]	0.509
ACE	6.66 [5.01, 7.65]	6.09 [4.85, 7.96]	0.636	6.69 [5.14, 8.01]	5.50 [4.69, 7.73]	0.197
ACE2	1.84 [1.27, 2.83]	5.71 [3.15, 16.14]	<0.001*	1.80 [1.23, 2.70]	4.81 [3.18, 14.02]	<0.001*
ALT-S	0.07 [0.05, 0.11]	0.12 [0.08, 0.21]	<0.001*	0.07 [0.05, 0.12]	0.13 [0.09, 0.21]	<0.001*
ACE-S	2.63 [1.89, 3.62]	1.60 [0.83, 2.06]	<0.001*	2.94 [2.24, 3.82]	1.77 [0.90, 2.32]	<0.001*

Table 2B. At 5-day time intervals

	Interval (days)	Non-severe	Severe	P
Angiotensin I	(1-6)	30.59 [8.16, 81.77]	84.29 [18.74, 424.07]	<0.05*
	(6-11)	22.70 [10.58, 68.61]	65.12 [20.49, 317.57]	<0.01*
	(11-16)	15.05 [6.08, 46.61]	61.03 [9.56, 278.48]	0.052
	(16-21)	11.20 [5.60, 23.38]	28.14 [13.13, 103.13]	0.248
Angiotensin II	(1-6)	54.04 [16.25, 132.99]	98.69 [32.89, 217.90]	0.091
	(6-11)	47.76 [15.03, 115.09]	72.82 [33.00, 235.84]	<0.05*
	(11-16)	29.15 [8.57, 113.15]	69.05 [22.42, 296.77]	<0.05*
	(16-21)	44.09 [4.36, 89.32]	57.43 [30.38, 159.41]	0.379
Angiotensin 1-7	(1-6)	1.50 [1.50, 7.26]	9.69 [1.50, 31.66]	<0.001*
	(6-11)	1.50 [1.50, 6.16]	22.47 [4.07, 85.19]	<0.001*
	(11-16)	1.50 [1.50, 4.99]	9.56 [3.45, 109.93]	<0.01*
	(16-21)	1.50 [1.50, 2.61]	4.16 [1.50, 38.03]	0.244
Angiotensin 1-5	(1-6)	3.22 [1.00, 7.07]	7.98 [2.57, 20.69]	<0.01*
	(6-11)	3.92 [2.02, 6.60]	22.84 [3.36, 80.96]	<0.001*
	(11-16)	3.91 [1.00, 9.06]	18.43 [8.07, 119.79]	<0.001*
	(16-21)	2.75 [1.00, 5.42]	10.97 [6.44, 63.49]	0.059
PRA-S	(1-6)	112.19 [39.15, 285.18]	238.57 [76.23, 586.81]	<0.05*
	(6-11)	108.94 [39.11, 230.67]	253.36 [67.12, 928.85]	<0.01*
	(11-16)	54.79 [21.96, 203.97]	171.69 [46.85, 918.76]	<0.05*
	(16-21)	60.09 [12.47, 124.74]	136.02 [67.82, 340.22]	0.17
ACE	(1-6)	6.45 [4.95, 7.76]	5.70 [4.75, 7.52]	0.664
	(6-11)	6.98 [5.19, 8.05]	5.44 [4.55, 7.70]	0.073
	(11-16)	6.11 [5.15, 8.17]	6.61 [4.66, 7.94]	0.852

	(16-21)	7.15 [5.68, 9.68]	6.94 [5.79, 9.58]	0.909
ACE2	(1-6)	1.75 [1.20, 3.02]	3.89 [1.77, 6.79]	<0.001*
	(6-11)	2.41 [1.46, 4.06]	7.58 [4.15, 19.83]	<0.001*
	(11-16)	1.77 [1.27, 5.45]	9.26 [4.00, 20.28]	<0.001*
	(16-21)	2.26 [1.51, 3.75]	5.78 [2.81, 18.35]	0.051
ALT-S	(1-6)	0.07 [0.04, 0.11]	0.10 [0.06, 0.17]	<0.01*
	(6-11)	0.08 [0.05, 0.13]	0.17 [0.12, 0.28]	<0.001*
	(11-16)	0.12 [0.07, 0.14]	0.21 [0.15, 0.30]	<0.001*
	(16-21)	0.14 [0.07, 0.20]	0.16 [0.09, 0.39]	0.446
ACE-S	(1-6)	2.66 [1.70, 3.67]	1.51 [0.86, 1.95]	<0.001*
	(6-11)	2.60 [1.76, 3.41]	1.27 [0.76, 1.84]	<0.001*
	(11-16)	3.01 [1.80, 4.09]	1.84 [1.04, 2.56]	0.079
	(16-21)	3.84 [3.07, 4.60]	2.31 [1.11, 3.32]	0.485

Values are presented as medians [with first, third quartiles]. Group comparisons (p values) were obtained using the Wilcoxon signed-rank test. All angiotensin concentrations, including PRA-S, are reported as pmol/L. ACE concentration is reported in µg/mL and ACE2 enzyme concentration in ng/mL. The angiotensin II:I ratio and the alternative RAS ratio were calculated using peptide levels in pmol/l and are reported as unitless values.

Figures

A

B

Figure 1

RAS metabolite levels

Figure 2

Key RAS enzymes

Figure 3

Alternative RAS

Figure 4

Angiotensin-II-to-Angiotensin-I ratio

Figure 5

Mixed effects models

Figure 6

RAS and patient survival in severe COVID-19

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [systemicRASCOVIDsupplementarymaterial.docx](#)